

PRESS RELEASE

Stockholm, Sweden, 30 September 2019



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 30 September 2019, the total number of shares in [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) amounts to 299,977,839 shares. All shares are common shares. The total number of votes is 299,977,839. The increase in the number of shares and votes results from an issue of 2,462,630 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under incentive programmes and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 30 September 2019 the company holds 5,886,356 common shares.

About Sobi™

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1,300 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com

Linda Holmström, Corporate Communication & Investor Relations
+ 46 708 734 095
linda.holmstrom@sobi.com

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 30 September 2019 at 08:30 CET.